SLC5A2 and Abnormal renal physiology: Previous randomized controlled trials suggested that poor glycemic control at baseline was related to good response to SGLT2 inhibitors [11,13], while renal dysfunction was associated with reduced efficacy of SGLT2 inhibitors in improving glycemic control [14].